Anti-angiogenic compounds
The present invention provides AA targeting compounds which comprise AA targeting agent-linker conjugates which are linked to a combining site of an antibody. Various uses of the compounds are provided, including methods to treat disorders connected to abnormal angiogenesis.
1. A compound having the formula:
or a pharmaceutically acceptable salt thereof.
2. A compound having the formula:
or a pharmaceutically acceptable salt thereof.
3. The compound of claim 1 , wherein said aldolase antibody is h38c2 lgG1.
4. The compound of claim 1 , wherein said aldolase antibody comprises a light chain comprising the amino acid sequence set forth in SEQ ID NO:40 and a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:41.
5. The compound of claim 2 , wherein said aldolase antibody is h38c2 lgG1.
6. The compound of claim 2 , wherein said aldolase antibody comprises a light chain comprising the amino acid sequence set forth in SEQ ID NO:40 and a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:41.
7. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 .
8. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 2 .
9. The pharmaceutical composition of claim 7 , further comprising a therapeutically effective amount of one or more chemotherapeutic agents.
10. The pharmaceutical composition of claim 9 , wherein the one or more chemotherapeutic agents are selected from the group consisting of 5-flurouracil, irinotecan, oxaliplatin, bevacizumab, and cetuximab.
11. The pharmaceutical composition of claim 8 , further comprising a therapeutically effective amount of one or more chemotherapeutic agents.
12. The pharmaceutical composition of claim 11 , wherein the one or more chemotherapeutic agents are selected from the group consisting of 5-flurouracil, irinotecan, oxaliplatin, bevacizumab, and cetuximab.